Renata Ferrarotto, MD, discusses the biologic rationale for and interim findings from a phase 1 study of Emi-Le in patients with aggressive ACC.
Diving Into B7-H4 Inhibition to Augment the ACC Treatment Paradigm
Emi-Le generated durable responses and encouraging PFS with manageable safety in patients with aggressive adenoid cystic carcinoma.
Glenn J. Hanna, MD, highlights interim efficacy and safety data from a phase 1 trial of Emi-Le in patients with aggressive adenoid cystic carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD
5